High-dose chemotherapy followed by autologous blood cell transplantation: A safe and effective outpatient approach

S. Glück, C. Des Rochers, C. Cano, M. Dorreen, C. Germond, K. Gill, P. Lopez, C. Sinoff

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

High-dose chemotherapy (HDCT) followed by autologous blood cell (ABC) transplantation has been used widely for patients with metastatic breast cancer (MBC). It has been shown by our group and others to be an effective means of achieving very high response rates including complete remission. Therefore, further reduction in toxicity and increased patient satisfaction is necessary. Fifty-three patients with MBC were enrolled in a feasibility study at our cancer centre with a three-step approach to outpatient observation after HDCT and ABC transplantation discharging our patients from hospital 6 days after reinfusion of ABC, 1 day after reinfusion of ABC and 1 day prior to reinfusion of ABC. The supportive care consisted of the use of 5-HT3 antagonists for nausea and vomiting, DMSO depletion, thorough body hygiene, prophylactic antibiotic, antifungal and virustatic drugs. In the event of febrile neutropenia, a standard evaluation and treatment was used. Only 22 patients were admitted for febrile neutropenia and two for haemorrhage. The median hospital stay was 2 days (range 1-7). The time to engraftment, need for transfusion and other toxicities were not different in patients who stayed entirely as outpatients. No toxic deaths occurred. In conclusion, HDCT followed by ABC transplantation can be safely administered to patients in the clinic with outpatient post-transplant observation.

Original languageEnglish
Pages (from-to)431-434
Number of pages4
JournalBone Marrow Transplantation
Volume20
Issue number6
StatePublished - Sep 2 1997
Externally publishedYes

Fingerprint

Cell Transplantation
Blood Cells
Outpatients
Drug Therapy
Febrile Neutropenia
Observation
Breast Neoplasms
Serotonin 5-HT3 Receptor Antagonists
Antifungal Agents
Poisons
Feasibility Studies
Ambulatory Care Facilities
Dimethyl Sulfoxide
Hygiene
Patient Satisfaction
Nausea
Vomiting
Length of Stay
Hemorrhage
Transplants

Keywords

  • Breast cancer
  • High-dose chemotherapy
  • Outpatient transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Glück, S., Des Rochers, C., Cano, C., Dorreen, M., Germond, C., Gill, K., ... Sinoff, C. (1997). High-dose chemotherapy followed by autologous blood cell transplantation: A safe and effective outpatient approach. Bone Marrow Transplantation, 20(6), 431-434.

High-dose chemotherapy followed by autologous blood cell transplantation : A safe and effective outpatient approach. / Glück, S.; Des Rochers, C.; Cano, C.; Dorreen, M.; Germond, C.; Gill, K.; Lopez, P.; Sinoff, C.

In: Bone Marrow Transplantation, Vol. 20, No. 6, 02.09.1997, p. 431-434.

Research output: Contribution to journalArticle

Glück, S, Des Rochers, C, Cano, C, Dorreen, M, Germond, C, Gill, K, Lopez, P & Sinoff, C 1997, 'High-dose chemotherapy followed by autologous blood cell transplantation: A safe and effective outpatient approach', Bone Marrow Transplantation, vol. 20, no. 6, pp. 431-434.
Glück S, Des Rochers C, Cano C, Dorreen M, Germond C, Gill K et al. High-dose chemotherapy followed by autologous blood cell transplantation: A safe and effective outpatient approach. Bone Marrow Transplantation. 1997 Sep 2;20(6):431-434.
Glück, S. ; Des Rochers, C. ; Cano, C. ; Dorreen, M. ; Germond, C. ; Gill, K. ; Lopez, P. ; Sinoff, C. / High-dose chemotherapy followed by autologous blood cell transplantation : A safe and effective outpatient approach. In: Bone Marrow Transplantation. 1997 ; Vol. 20, No. 6. pp. 431-434.
@article{9f66c87ad21c4360bf7d45bd6711e4d1,
title = "High-dose chemotherapy followed by autologous blood cell transplantation: A safe and effective outpatient approach",
abstract = "High-dose chemotherapy (HDCT) followed by autologous blood cell (ABC) transplantation has been used widely for patients with metastatic breast cancer (MBC). It has been shown by our group and others to be an effective means of achieving very high response rates including complete remission. Therefore, further reduction in toxicity and increased patient satisfaction is necessary. Fifty-three patients with MBC were enrolled in a feasibility study at our cancer centre with a three-step approach to outpatient observation after HDCT and ABC transplantation discharging our patients from hospital 6 days after reinfusion of ABC, 1 day after reinfusion of ABC and 1 day prior to reinfusion of ABC. The supportive care consisted of the use of 5-HT3 antagonists for nausea and vomiting, DMSO depletion, thorough body hygiene, prophylactic antibiotic, antifungal and virustatic drugs. In the event of febrile neutropenia, a standard evaluation and treatment was used. Only 22 patients were admitted for febrile neutropenia and two for haemorrhage. The median hospital stay was 2 days (range 1-7). The time to engraftment, need for transfusion and other toxicities were not different in patients who stayed entirely as outpatients. No toxic deaths occurred. In conclusion, HDCT followed by ABC transplantation can be safely administered to patients in the clinic with outpatient post-transplant observation.",
keywords = "Breast cancer, High-dose chemotherapy, Outpatient transplantation",
author = "S. Gl{\"u}ck and {Des Rochers}, C. and C. Cano and M. Dorreen and C. Germond and K. Gill and P. Lopez and C. Sinoff",
year = "1997",
month = "9",
day = "2",
language = "English",
volume = "20",
pages = "431--434",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - High-dose chemotherapy followed by autologous blood cell transplantation

T2 - A safe and effective outpatient approach

AU - Glück, S.

AU - Des Rochers, C.

AU - Cano, C.

AU - Dorreen, M.

AU - Germond, C.

AU - Gill, K.

AU - Lopez, P.

AU - Sinoff, C.

PY - 1997/9/2

Y1 - 1997/9/2

N2 - High-dose chemotherapy (HDCT) followed by autologous blood cell (ABC) transplantation has been used widely for patients with metastatic breast cancer (MBC). It has been shown by our group and others to be an effective means of achieving very high response rates including complete remission. Therefore, further reduction in toxicity and increased patient satisfaction is necessary. Fifty-three patients with MBC were enrolled in a feasibility study at our cancer centre with a three-step approach to outpatient observation after HDCT and ABC transplantation discharging our patients from hospital 6 days after reinfusion of ABC, 1 day after reinfusion of ABC and 1 day prior to reinfusion of ABC. The supportive care consisted of the use of 5-HT3 antagonists for nausea and vomiting, DMSO depletion, thorough body hygiene, prophylactic antibiotic, antifungal and virustatic drugs. In the event of febrile neutropenia, a standard evaluation and treatment was used. Only 22 patients were admitted for febrile neutropenia and two for haemorrhage. The median hospital stay was 2 days (range 1-7). The time to engraftment, need for transfusion and other toxicities were not different in patients who stayed entirely as outpatients. No toxic deaths occurred. In conclusion, HDCT followed by ABC transplantation can be safely administered to patients in the clinic with outpatient post-transplant observation.

AB - High-dose chemotherapy (HDCT) followed by autologous blood cell (ABC) transplantation has been used widely for patients with metastatic breast cancer (MBC). It has been shown by our group and others to be an effective means of achieving very high response rates including complete remission. Therefore, further reduction in toxicity and increased patient satisfaction is necessary. Fifty-three patients with MBC were enrolled in a feasibility study at our cancer centre with a three-step approach to outpatient observation after HDCT and ABC transplantation discharging our patients from hospital 6 days after reinfusion of ABC, 1 day after reinfusion of ABC and 1 day prior to reinfusion of ABC. The supportive care consisted of the use of 5-HT3 antagonists for nausea and vomiting, DMSO depletion, thorough body hygiene, prophylactic antibiotic, antifungal and virustatic drugs. In the event of febrile neutropenia, a standard evaluation and treatment was used. Only 22 patients were admitted for febrile neutropenia and two for haemorrhage. The median hospital stay was 2 days (range 1-7). The time to engraftment, need for transfusion and other toxicities were not different in patients who stayed entirely as outpatients. No toxic deaths occurred. In conclusion, HDCT followed by ABC transplantation can be safely administered to patients in the clinic with outpatient post-transplant observation.

KW - Breast cancer

KW - High-dose chemotherapy

KW - Outpatient transplantation

UR - http://www.scopus.com/inward/record.url?scp=0742316670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0742316670&partnerID=8YFLogxK

M3 - Article

C2 - 9313874

AN - SCOPUS:0742316670

VL - 20

SP - 431

EP - 434

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -